{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:17:32Z","timestamp":1770473852971,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":3202,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:p>The objective of this study was to determine the reliability of omeprazole as a marker for CYP2C19 activity in Chinese subjects. In 27 healthy male Chinese subjects, the CYP2C19 phenotype was first determined with the standard mephenytoin hydroxylation index (HI) method. Subsequently, the subjects were randomized in a three\u2010way crossover manner to receive an oral 40\u2010mg dose from each of three omeprazole formulations (as part of a bioequivalence study). Multiple blood samples were obtained over 12 hours, and plasma concentrations of omeprazole, 5\u2010hydroxyomeprazole, and omeprazole sulfone were determined by a high\u2010performance liquid chromatography (HPLC) method. Individual CYP2C19 genotype was determined by the polymerase chain reaction\/restriction fragment length polymorphism method. To assess the specificity for CYP2C19 activity, the hydroxylation metabolic ratio (MR) of omeprazole (AUC<jats:sub>omeprazole<\/jats:sub>\/AUC<jats:sub>5\u2010hydroxyomeprazole<\/jats:sub>) was compared to mephenytoin HI and related to CYP2C19 genotype status. The inter\u2010 and intrasubject variabilities of MR were also calculated, and their magnitudes were compared. The intersubject MR varied more than 20 fold. Among the subjects, there was a gene\u2010dose effect, and the mean MR was 1.76, 3.45, and 33.08, respectively, in the homozygous extensive metabolizers (wt\/wt, <jats:italic>n<\/jats:italic> = 9), heterozygous extensive metabolizers (wt\/m1 or wt\/m2, <jats:italic>n<\/jats:italic> = 10), and poor metabolizers (m1\/m1 or m1\/m2, <jats:italic>n<\/jats:italic> = 7). However, the coefficients of variation for intrasubject MR only ranged from 4.5% to 33.7% over the three periods with the three formulations. The phenotype based on MR was concordant with HI. In view of the clear gene\u2010dose effect, concordance with mephenytoin HI, and low intrasubject variability, omeprazole MR following a 40\u2010mg oral dose can be considered as a specific and sensitive marker for CYP2C19 activity in Chinese subjects<\/jats:p>","DOI":"10.1177\/0091270004265702","type":"journal-article","created":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T20:23:25Z","timestamp":1084566205000},"page":"582-589","source":"Crossref","is-referenced-by-count":42,"title":["Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene\u2010Dose Effect and Intrasubject Variability"],"prefix":"10.1002","volume":"44","author":[{"given":"Ophelia Q. P.","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert H. L.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M. Y.","family":"Waye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses S. S.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011035007591"},{"key":"e_1_2_5_3_2","first-page":"331","article-title":"The N\u2010demethylation of imipramine correlates with the oxidation of S\u2010mephenytoin (S\/R ratio): a population study","volume":"35","author":"Skjelbo E","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.155"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.65"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.40"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/004982599238056"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241120-00002"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1093\/clinchem\/45.12.2273","article-title":"Frequencies of the defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4","volume":"45","author":"Garcia\u2010Barcel\u00f3 M","year":"1999","journal-title":"Clin Chem"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)40694-6"},{"key":"e_1_2_5_11_2","first-page":"594","article-title":"Identification of a new genetic defect responsible for the polymorphism of S\u2010mephenytoin metabolism in Japanese","volume":"46","author":"Morais SM","year":"1994","journal-title":"Mol Pharmacol"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.815"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04099.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05542.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04488.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199512000-00004"},{"key":"e_1_2_5_17_2","first-page":"52","article-title":"Oxidation metabolism of omeprazole in human liver microsomes: cosegregation with S\u2010mephenytoin 4\u2032\u2010hydroxylations","volume":"266","author":"Chiba K","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb00410.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90229-5"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90192-2"},{"key":"e_1_2_5_21_2","first-page":"1195","article-title":"Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S\u2010mephenytoin 4\u2010hydroxylation recruited from an oriental population","volume":"262","author":"Sohn DR","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90004-1"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-12-199812150-00006"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90129-0"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199612000-00008"},{"key":"e_1_2_5_26_2","first-page":"277","article-title":"Pharmacogenetic association between the formation of 4\u2010hydroxymephenytoin and a new metabolite of S\u2010mephenytoin in man","volume":"15","author":"Wedlund PJ","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(92)80395-7"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199202000-00005"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199702000-00008"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199404000-00018"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.126174"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199704000-00004"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70106-2"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.108949"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270004265702","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270004265702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:51:45Z","timestamp":1697525505000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270004265702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1177\/0091270004265702"],"URL":"https:\/\/doi.org\/10.1177\/0091270004265702","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}